HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meta, J. Articles by Czernin, J. Search for Related Content PubMed PubMed Citation Articles by Meta, J. Articles by Czernin, J.

Impact of ¹⁸F-FDG PET on Managing Patients with Colorectal Cancer: The Referring Physician’s Perspective

Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Clinic/Nuclear Medicine, University of California, Los Angeles, School of Medicine, Los Angeles; and Northern California PET Imaging Center, Sacramento, California

Whole-body PET imaging with ¹⁸F-FDG has been used successfully to stage colorectal cancer. However, the impact of FDG PET on patient management from the referring physician’s point of view has not been determined. Methods: A questionnaire was sent to referring physicians to determine whether and how PET altered the management of colorectal cancer patients. Management changes, when present, were classified as intermodality (e.g., medical to surgical, surgical to radiation, medical to no treatment) or intramodality (e.g., altered medical, surgical, or radiotherapy approach). Results: Of 60 responses from referring physicians, changes in clinical stage were reported for 25 patients (42%). Among these, the disease was upstaged in 20 patients (80%) and downstaged in 5 patients (20%). The PET findings contributed to intermodality management changes in 22 of the 60 patients (37%), intramodality changes in 11 patients (18%), a combination of management changes in 4 patients (7%), and no change in 19 patients (32%). Two of the 60 patients (3%) had other changes, and no response to this question was received for the remaining 2 patients (3%). As a result of PET findings, physicians avoided major surgery in 41% of patients for whom surgery was the intended treatment. Conclusion: This survey-based study of referring physicians shows that FDG PET had a major impact on the management of colorectal cancer patients and contributed to changes in clinical stage and major management decisions in >40% of patients.

Key Words: PET • colorectal cancer • survey

This article has been cited by other articles:

				F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J.-P. Lotz, P. Ruszniewski, P. Rougier, F. Duron, P. Bouchard, J.-D. Grange, et al. Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1295 - 1301. [Abstract] [Full Text] [PDF]

				S. Ben-Haim and P. Ell 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response J. Nucl. Med., January 1, 2009; 50(1): 88 - 99. [Abstract] [Full Text] [PDF]

				A. M. Scott, D. H. Gunawardana, B. Kelley, J. G. Stuckey, A. J. Byrne, J. E. Ramshaw, and M. J. Fulham PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study J. Nucl. Med., September 1, 2008; 49(9): 1451 - 1457. [Abstract] [Full Text] [PDF]

				B. E. Hillner, D. Liu, R. E. Coleman, A. F. Shields, I. F. Gareen, L. Hanna, S. H. Stine, and B. A. Siegel The National Oncologic PET Registry (NOPR): Design and Analysis Plan J. Nucl. Med., November 1, 2007; 48(11): 1901 - 1908. [Abstract] [Full Text] [PDF]

				M. J. Lindsay, B. A. Siegel, S. R. Tunis, B. E. Hillner, A. F. Shields, B. P. Carey, and R. E. Coleman The National Oncologic PET Registry: Expanded Medicare Coverage for PET Under Coverage with Evidence Development Am. J. Roentgenol., April 1, 2007; 188(4): 1109 - 1113. [Abstract] [Full Text] [PDF]

				W. C. Hanna, T. A. Ponsky, G. D. Trachiotis, and S. M. Knoll Colon Cancer Metastatic to the Lung and the Thyroid Gland Arch Surg, January 1, 2006; 141(1): 93 - 96. [Abstract] [Full Text] [PDF]

				T. Akhurst, T. J. Kates, M. Mazumdar, H. Yeung, E. R. Riedel, B. M. Burt, L. Blumgart, W. Jarnagin, S. M. Larson, and Y. Fong Recent Chemotherapy Reduces the Sensitivity of [18F]Fluorodeoxyglucose Positron Emission Tomography in the Detection of Colorectal Metastases J. Clin. Oncol., December 1, 2005; 23(34): 8713 - 8716. [Abstract] [Full Text] [PDF]

				J.-H. Kim, J. Czernin, M. S. Allen-Auerbach, B. S. Halpern, B. J. Fueger, J. R. Hecht, O. Ratib, M. E. Phelps, and W. A. Weber Comparison Between 18F-FDG PET, In-Line PET/CT, and Software Fusion for Restaging of Recurrent Colorectal Cancer J. Nucl. Med., April 1, 2005; 46(4): 587 - 595. [Abstract] [Full Text] [PDF]

				C.-y. O. Wong, R. Salem, F. Qing, K. T. Wong, D. Barker, V. Gates, R. Lewandowski, E. A. Hill, H. J. Dworkin, and C. Nagle Metabolic Response After Intraarterial 90Y-Glass Microsphere Treatment for Colorectal Liver Metastases: Comparison of Quantitative and Visual Analyses by 18F-FDG PET J. Nucl. Med., November 1, 2004; 45(11): 1892 - 1897. [Abstract] [Full Text] [PDF]

				B. E. Hillner, R. Tunuguntla, and M. Fratkin Clinical Decisions Associated With Positron Emission Tomography in a Prospective Cohort of Patients With Suspected or Known Cancer at One United States Center J. Clin. Oncol., October 15, 2004; 22(20): 4147 - 4156. [Abstract] [Full Text] [PDF]

				B B Chin and R L Wahl 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies Gut, June 1, 2003; 52(90004): iv23 - 29. [Abstract] [Full Text] [PDF]

				E. V. Dizendorf, B. G. Baumert, G. K. von Schulthess, U. M. Lutolf, and H. C. Steinert Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients for Radiation Therapy J. Nucl. Med., January 1, 2003; 44(1): 24 - 29. [Abstract] [Full Text] [PDF]

				M. A. Seltzer, C. S. Yap, D. H. Silverman, J. Meta, C. Schiepers, M. E. Phelps, S. S. Gambhir, J. Rao, P. E. Valk, and J. Czernin The Impact of PET on the Management of Lung Cancer: The Referring Physician's Perspective J. Nucl. Med., June 1, 2002; 43(6): 752 - 756. [Abstract] [Full Text] [PDF]

				E. Even-Sapir, H. Lerman, A. Figer, M. Rabau, G. Livshitz, M. Inbar, and M. Gutman Role of 18F-FDG Dual-Head Gamma-Camera Coincidence Imaging in Recurrent or Metastatic Colorectal Carcinoma J. Nucl. Med., May 1, 2002; 43(5): 603 - 609. [Abstract] [Full Text] [PDF]

				C. S. Yap, M. A. Seltzer, C. Schiepers, S. S. Gambhir, J. Rao, M. E. Phelps, P. E. Valk, and J. Czernin Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients with Breast Cancer: The Referring Physician's Perspective J. Nucl. Med., September 1, 2001; 42(9): 1334 - 1337. [Abstract] [Full Text] [PDF]

				H. Schoder, J. Meta, C. Yap, M. Ariannejad, J. Rao, M. E. Phelps, P. E. Valk, J. Sayre, and J. Czernin Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma J. Nucl. Med., August 1, 2001; 42(8): 1139 - 1143. [Abstract] [Full Text] [PDF]